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ABSTRACT 
Background    Indirubin, a constituent of the Chinese 
herbal medicine “Qing-Dai,” has anti-cancer and 
anti-inflammatory activities. We aimed to evaluate the 
efficacy of indirubin for ameliorating colonic inflamma-
tion in a mouse model of inflammatory bowel disease. 
Methods    Mice with dextran sulfate sodium (DSS)-
induced acute and chronic colitis were treated with 
indirubin in their diet. Clinical and histologic changes 
were evaluated. In addition, colon levels of interleukin-6, 
a critical pro-inflammatory mediator, was detected by 
enzyme-linked immunosorbent assay. 
Results    In the model of acute colitis, indirubin treat-
ment improved the loss of body weight. Histology of co-
lonic tissue revealed that indirubin treatment improved 
the histology grading of colitis (P = 0.02), the extent of 
submucosal fibrosis (P = 0.018), the number of mucosal 
toluidine blue-positive cells (P = 0.004) and colon length 
(P = 0.01). In the model of chronic colitis, indirubin 
treatment had no significant effect on pathologic findings 
except for colon length (P = 0.003). However, indirubin 
administration significantly reduced colon levels of 
interleukin-6 in the chronic-colitis model (P = 0.001). 
Conclusion    Our study clearly showed that oral intake 
of indirubin can improve murine DSS-induced colitis 
(which mimics human inflammatory bowel disease).
Key words    Chinese herbal medicine; DSS-induced 
colitis model; indirubin; inflammatory bowel disease; 
Qing-Dai 
Indirubin is an active ingredient of a traditional Chinese 
medicine (TCM) named “Danggui Longui Wan,” which 
has potent activity against myelocytic leukemia.1, 2 Indirubin 
is the purple component of the dye indigo blue, which is ex-
tracted from plants such as Polygonum tinctorium Lour and 
Indigofera tinctoria. Indirubin is a 3,2’-bisindole, a stable 
isomer of indigo (Fig. 1). 
 Indirubin has anti-inflammatory and anti-cancer 
activities. Kunikata et al. reported that indirubin inhibits 
inflammatory reactions in delayed-type hypersensitivity 
in mice.3 They described the effects of indirubin on 
cytokine production by immunocompetent cells and on 
the delayed-type hypersensitivity reaction in vitro, in 
which interferon-γ has a crucial role. Mak et al. reported 
that indirubin suppresses expression of the influenza 
virus-induced chemokine RANTES in human bronchial 
epithelial cells.4 Moreover, indirubin has shown potent 
anti-proliferative activity in various human cancer cells.5 
In a recent prospective study, Sugimoto et al. reported 
that the Chinese herbal medicine “Qing-Dai,” (which 
contains indole compounds, including indirubin) was 
effective for patients with ulcerative colitis (UC), which 
is involved in inflammatory bowel disease (IBD).6
 Oral administration of the sulfated polysaccharide 
dextran sulfate sodium (DSS) induces colitis in mice,7, 8 
rats,9 guinea pigs,10 and hamsters.11 Okayasu et al. 
reported a UC model involving oral administration of 
DSS in BALB/c and CBA/J mice.7 Depending on the 
time-course of oral administration of DSS in drinking 
water, it could induce acute or chronic colitis in mice.7 
DSS-induced colitis exhibits several morphologic and 
pathophysiologic features similar to those observed 
in human IBD, including production of cytokines and 
other inflammatory mediators, as well as leukocyte 
infiltration.7, 8, 12 A DSS-induced model of colitis in 
animals has been used to examine the effect of various 
anti-inflammatory agents against IBD.13–17    
 Herein, we examined the effect of indirubin on 
DSS-induced colitis in mice. We showed, for the first 
time, that indirubin treatment can improve murine DSS-
induced colitis.
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MATERIALS AND METHODS
Animals 
Female BALB/c mice (6 weeks; 20–22 g) 
were obtained from Charles River Japan 
(Kanagawa, Japan). The mice were treated in 
accordance with the Guidelines for Animal 
Experimentation set by Tottori University 
(06-S-76) (Tottori, Japan). Animals were 
housed in rooms at a controlled temperature 
of 24 ± 2 °C and light-dark cycle with a 
maximum of six mice per cage. Mice were 
fed with standard pellets (MF; Oriental 
Yeast, Tokyo, Japan) and had free access to 
drinking water.
 
Chemicals
DSS (molecular weight: 36,000–50,000) 
was purchased from ICN Biomedicals 
(Eschwege, Germany). Indirubin was syn-
thesized by Asahi Kasei Finechem (Osaka, 
Japan).18 
 
Induction of colitis and treatment with 
indirubin
Acute colitis was induced with 2% DSS 
given in drinking water for ≤ 6 days (n = 12). 
Mice were treated with indirubin (0.05 μg/
g/day) in their diet (n = 6). Mice not given 
Fig. 1. Chemical structures of indirubin (A) and indigo (B). 
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Fig. 2. Experimental protocols for DSS-induced acute and chronic colitis experi-
ments. (A) In acute-colitis studies, mice were subjected to one, 6-day DSS cycle. 
Mice were fed a normal or indirubin-supplemented diet, commencing 5 days 
before the start of the experiment and continuing until the end of the experiment. 
Mice were killed on day-6 (arrow). (B) For the study of chronic colitis, mice 
were subjected to three consecutive DSS cycles. Each cycle consisted of a DSS-
administration period followed by a recovery period in which water was admin-
istrated. Mice were fed a normal or indirubin-supplemented diet commencing 5 
days before the start of the experiment and continuing until the end of the third 
DSS cycle. All surviving mice were killed at the completion of the third DSS 
cycle (arrow). DSS, dextran sulfate sodium. 
DSS or indirubin were used as the control group (n = 
6). Chronic colitis was induced by administration of 2% 
DSS in three cycles for 6 days, interspersed with 8 days 
of giving drinking water (n = 12). Mice were treated 
with indirubin (0.05 μg/g/day) in their diet (n = 6). Mice 
not given DSS or indirubin were used as the control 
group (n = 6).
 Indirubin treatment was started before the 5 days of 
DSS exposure and continued throughout the observation 
period in acute and chronic models of colitis (Fig. 2).
Evaluation of colitis and drug effects
General parameters recorded in the experiments were 
body weight and food consumption. After the end of the 
experiment, all mice were killed by cervical dislocation. 
Immediately, large intestines were resected between the 
ileocecal junction and proximal rectum. The length of 
the large intestine was measured to evaluate the preven-
tive effect of indirubin treatment on shortening of the 
large intestine accompanied by colitis. Large intestines 
were placed on filter papers to measure their length, 
after which they were opened longitudinally so that their 
contents could be removed. 
 The colon was divided into two equal segments 
(proximal and distal) and fixed in neutral-buffered 10% 
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formalin. All slides were stained with hematoxylin and 
eosin. For histopathologic evaluation of tissue damage, 
areas of inflammatory lesions were evaluated under light 
microscopy and quantified using the method of Cooper 
et al.,8 with minor modifications (Table 1). Grading was 
based on pathologic changes: 0, intact crypt; 1, loss of 
the basal one-third of the crypt; 2, loss of the basal two-
thirds of the crypt; 3, loss of the entire crypt with the 
surface epithelium remaining intact; 4, loss of the entire 
crypt and surface epithelium (erosion). These changes 
were quantitated according to percentage involvement 
by the disease: (1) 1–25%; (2) 26–50%; (3) 51–75%; (4) 
76–100%. Each section was scored with a grade and 
percentage area involvement, with the product of the two 
being a “crypt score.” The scores for each tissue were 
summed and divided by the number of pieces of tissue to 
give a “histology score.” Colitis was not observed in the 
proximal colon, so only the distal colon was evaluated 
in all cases. The distal colon was divided into 4 sections 
and evaluated. 
 For histologic evaluation of the extent of fibrosis in 
the submucosa, all slides were stained with Masson’s 
trichrome. The extent of fibrosis per 1-cm of the distal 
colon was calculated as “percentage involvement.” 
 Mast cells were identified by staining (toluidine blue) 
(Fig. 3). The number of mucosal toluidine blue-positive 
cells in the distal colon was counted, and number per 
1-cm was calculated. 
Table 1. Histology grading of colitis
Feature Score Description
Damage 0 None
1 Loss of the basal 1/3 of the crypt
2 Loss of the basal 2/3 of the crypt
3 Loss of entire crypt but intact surface epithelial cells
4 Loss of both the entire crypt and the surface epithelial cells
Percentage 1 1–25%
area 2 26–50%
involvement 3 51–75%
4 76–100%
Enzyme-linked immunosorbent assay (ELISA)
After killing, the rectum (5 mm × 5 mm) was excised. 
Feces were removed by gentle washing in physiologic 
(0.9%) saline. The rectum tissue was homogenized and 
the concentration of the interleukin (IL)-6 level in the 
supernatant was measured by sandwich ELISA using 
paired antibodies according to manufacturer (RayBio, 
Norcross, GA) recommendations. 
Statistical analyses
Data are the mean ± standard deviation (SD). Data 
comparisons were made using the Student’s t-test and 
Pearson correlation to test the correlation between vari-
ables. P < 0.05 was considered significant.
RESULTS
Mice administered only indirubin (0.05 μg/g/day) in 
their diet for 1 month suffered no pathologic change, 
compared with the control group, in terms of body 
weight, colonic histology, and IL-6 content in the rectum 
(data not shown).
General features
Acute colitis 
There was no difference in consumption of DSS–water 
between the groups given and not given indirubin in 
acute and chronic models of colitis. Administration of 
2% DSS for 6 days resulted in severe colitis with a sig-
nificant reduction in body weight and food intake from 
day-4. On the final day of observation, the mean in-
crease in body weight was 0.44 ± 2.1 g in mice not given 
indirubin, and 1.67 ± 0.5 g in mice given indirubin, and 
this difference was significant (P = 0.03) [Fig. 4A]. The 
mean food intake per mouse per day was 4.80 ± 1.0 g 
in mice not given indirubin, and 4.36 ± 0.58 g in mice 
given indirubin, but the difference was not significant (P 
= 0.31). 
 The length of the large intestine was 13.4 ± 0.58 
cm in mice not given DSS or indirubin (control), 10.2 ± 
0.52 cm in colitis mice not given indirubin, and 11.1 ± 
Fig. 3. Intracellular granules of mast cell were stained with 
toluidine blue (arrow). It shows metachromasia and shows reddish 
purple color. Bar = 0.2 mm.
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Fig. 4. Changes (0, baseline) in body weight (mean ± SE) of mice receiving water (control), DSS, or DSS and indirubin in (A) acute colitis 
and (B) chronic colitis. DSS, dextran sulfate sodium; N.S, not significant.
0.58 cm in colitis mice given indirubin (Fig. 5A). Thus, 
indirubin showed a significant preventive effect on short-
ening of the large intestine in our model of acute colitis (P 
= 0.02) [Fig. 5A]. 
Chronic colitis 
Stable chronic colitis could be achieved by three repeat 
6-day cycles of DSS interrupted by 8-day recovery 
periods using water not containing DSS. Initially, mice 
manifested diarrhea and blood in feces and body-weight 
loss in the first cycle of administration of 2% DSS. 
However, these signs improved after drinking water for 
the next 8 days. On subsequent administrations of DSS 
(three cycles), these symptoms improved during the 
8-day period of water consumption (Fig. 4B). Only one 
mouse receiving 2% DSS without indirubin died with 
severe loss of body weight (16.1 g) on day-18. On the fi-
nal day of observation, the mean body weight increased 
from 2.76 ± 0.4 g in mice not given indirubin to 3.53 ± 1.1 
g in mice given indirubin, and this difference was not 
significant (P = 0.18) [Fig. 4B]. The mean food intake 
per mouse per day was 5.31 ± 1.7 g in mice not given 
indirubin, and 4.64 ± 1.6 g in mice given indirubin, and 
this difference was not significant (P = 0.11). 
 The length (mean ± SD) of the large intestine was 
12.9 ± 0.75 cm in mice not given DSS and indirubin 
A
B
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Fig. 5. Effect of indirubin on the length of the large intestine of mice with DSS-induced colitis. (A) Acute-colitis model on day-6. (B) 
Chronic-colitis model on day-42. The large intestine was isolated, and its length measured. Median scores are indicated by horizontal 
lines. DSS, dextran sulfate sodium; N.S, not significant.
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(control group), 10.4 ± 0.42 cm in the chronic-colitis 
model without indirubin, and 11.8 ± 0.68 cm in the 
chronic-colitis model with indirubin (Fig. 5B). Thus, in-
dirubin prevented a significant reduction in colon length 
in the chronic-colitis model (P = 0.003). 
Histology 
Acute colitis 
Representative histologic findings are shown in Figs. 
6A–C. DSS induced erosive colitis in a variable man-
ner (Fig. 6B). The histology score was 8.83 ± 2.2 in 
acute-colitis mice not given indirubin and 5.16 ± 2.4 in 
acute-colitis mice given indirubin, and this difference 
was significant (P = 0.02) [Fig. 7A]. The extent of 
submucosal fibrosis was 40.4 ± 8.9% in mice not given 
indirubin and 22.2 ± 13% in mice given indirubin, and 
this difference was significant (P = 0.018). The histology 
score correlated well with body-weight reduction ac-
cording to the Pearson’s correlation coefficient test (r = 
0.62).
 Administration of 2% DSS for 6 days resulted in 
a marked increase in the number of mucosal toluidine 
blue-positive cells. The number of mucosal toluidine 
blue-positive cells was 334 ± 64/cm in mice not given 
indirubin and 163 ± 89/cm in mice given indirubin, and 
this difference was significant (P = 0.004).
Chronic colitis 
The histology score was 6.40 ± 0.89 in chronic-colitis 
mice not given indirubin and 5.16 ± 2.0 in chronic-colitis 
mice given indirubin, and this difference was not sig-
nificant (P = 0.24) [Fig. 7B]. The extent of submucosal 
fibrosis was 28.0 ± 11.8% in mice not given indirubin 
and 36.7 ± 19.2% in mice given indirubin, and this 
difference was not significant (P = 0.40). The histology 
score did not correlate well with body-weight reduction 
according to the Pearson’s correlation coefficient test (r 
= 0.21). 
 The number of mucosal toluidine blue-positive cells 
was 138 ± 109/cm in mice not given indirubin and 129 ± 
77/cm in mice given indirubin, and this difference was 
not significant (P = 0.88).
Changes in levels of pro-inflammatory cytokines
We measured IL-6 content in the rectum of mice in the 
presence and absence of indirubin at day-6. The IL-6 
level was 541 ± 728 pg/mL in the rectum of mice not 
given indirubin and 154 ± 217 pg/mL in mice given 
indirubin, and this difference was not significant (P = 
0.24) in acute colitis [Fig. 8A]. The IL-6 level was 69.6 
± 14.2 pg/mL in the rectum of mice not given indirubin 
and 28.4 ± 13.1 pg/mL in mice given indirubin, and this 
difference was significant (P = 0.001) in chronic colitis 
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Fig. 7. Histology score of colitis in mice not given DSS or indirubin (control), given DSS but not indirubin, or given DSS and indirubin. 
Mice were administered indirubin (0.05 μg/g/day, p.o.) in their diet. (A) Acute-colitis model on day-6. (B) Chronic-colitis model on day-
42. The large intestine was isolated, and morphologic analyses undertaken. The histopathologic severity of colitis was calculated. 
DSS, dextran sulfate sodium; N.S, not signifi cant; p.o., per os.
Fig. 6. Histology (H&E stain) of colonic samples taken from 
mice not given DSS or indirubin (control) (A), given DSS and 
indirubin (B) or given DSS but not indirubin (C). Compared 
with that of control, the colons of DSS-induced colitis mice 
showed: complete destruction of epithelial architecture with 
loss of crypts and epithelial integrity; submucosal fi brosis and 
edema; intense infi ltration of infl ammatory cells in all layers. 
Indirubin treatment attenuated morphologic damage but 
showed mild infi ltration of infl ammatory cells. Bar = 1 mm. 
DSS, dextran sulfate sodium.
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[Fig. 8B]. Serum levels of IL-6 were not detected in 
mice suffering from acute or chronic colitis. 
DISCUSSION
IBD includes the common gastrointestinal diseases UC 
and Crohn’s disease, and their incidence is increasing 
worldwide. Therapies such as mesalamine, corticoste-
roids, and thiopurines, in general, provide only transient 
or marginal relief, so the development of alternative 
treatments is of great interest. TCM, which is based to 
a large extent on the use of plant extracts, constitutes a 
valuable approach for the discovery of new drugs.   
 A recent clinical trial showed that the Chinese 
herbal medicine Qing-Dai (which contains indirubin) 
was effective for inducing remission in patients with 
UC.6 Dr. Amano (Hiroshima, Japan) has treated more 
than 4500 patients with intractable UC using Qing-
Dai. The latter is extracted from the leaves and stems 
of plant species such as Baphicacanthus cusia (Nees) 
Bremek. (Acanthaceae), Polygonum tinctorium Ait. 
(Polygonaceae), and Isatis indigotia Fort. (Cruciferae). 
Qing-Dai contains several organic components such 
as indigo, indirubin, tryptanthrin, sterols, and amino 
acids.19
 Indirubin is a well-known TCM used for the treat-
ment of myelocytic leukemia. Several clinical trials 
using indirubin have been undertaken for the treatment 
of chronic myelocytic and chronic granulocytic leu-
kemia in China.20–23 In one study undertaken by the 
Cooperative Group of Clinical Therapy of Indirubin, 
26% of 314 patients with chronic myelocytic leukemia 
showed complete remission, and 33% showed partial 
remission, in response to indirubin treatment.21 Toxicity 
was low and side effects were limited to mild abdominal 
pain, diarrhea, nausea and vomiting. There were three 
cases of reversible pulmonary arterial hypertension and 
cardiac insufficiency.24 
 Indirubin exhibits only minor toxicity in animal 
models.25 For example, dogs given a dose of indirubin 
25-times that used for human therapy (according to body 
weight) continuously for 6 months showed diarrhea and 
some damage to the liver, with no change in hematopoi-
esis, electroencephalographic activity or renal function.26 
In our animal study, indirubin treatment for 1 month 
did not elicit unfavorable clinical or histologic changes 
in mice not given DSS (data not shown). Therefore, the 
therapeutic effect of indirubin can be examined without 
inducing toxicity in clinical studies.
 Among the various models of chemically induced 
colitis, the DSS-induced colitis model is used widely 
because of its simplicity and many similarities with hu-
man UC. This model has advantages and disadvantages 
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Fig. 8. Effects of indirubin treatment on colonic cytokine expression in DSS-induced colitis. (A) Acute-colitis model on day-6. (B) 
Chronic-colitis model on day-42. Mice were killed. A rectum sample (5 mm × 5 mm) was excised and homogenized. Tissue content of 
IL-6 was measured by ELISA specific for mouse IL-6. Median scores are indicated by horizontal lines. DSS, dextran sulfate sodium; 
ELISA, Enzyme-linked immunosorbent assay; N.S, not significant.
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that must be considered when employed.27 Mice show 
different susceptibilities and responsiveness to DSS-
induced colitis. Several mechanisms for DSS colitis have 
been proposed. In one representative mechanism, DSS 
administration blocks bacterial phagocytosis by macro-
phages in the lamina propria and causes direct injury to 
the epithelium, leading to early shortening and erosions 
in crypts.28, 29 Varying responses to DSS appear to be de-
pendent on the inbred strain,30 DSS concentration,31 mo-
lecular weight of DSS,32 and duration of DSS exposure.8 
In our study, significant differences in the consumption 
of DSS–water were not observed between groups given 
or not given indirubin. We, therefore, concluded that 
consumption of DSS–water did not affect the severity 
of DSS-induced colonic injury in mice. Kitajima et al. 
reported that the severity and primary location of colitis 
differ depending upon the molecular weight of DSS ad-
ministered in mice. Colitis was observed predominantly 
in the cecum and upper colon in mice given DSS of 
molecular weight 5 kD. In mice given DSS of molecular 
weight 40 kD, colitis was more prominent in the distal 
colon.32 In our study, colitis was localized to the distal 
colon in all mice because DSS of molecular weight 
36–50 kD was used for oral administration.
 A histology grading system showed that indiru-
bin improved DSS-induced acute colitis, but was not 
prominent in the chronic-colitis model. In the latter, the 
region with crypt loss had been displaced with epithelial 
dysplasia. Therefore, there might not be significant 
differences in histology grades between mice given DSS 
and those not given DSS. Histology demonstrated colla-
gen accumulation in the submucosal region of intestines, 
which could be the cause of intestinal shortening in the 
colitis model. Smooth muscle cells, subepithelial myofi-
broblasts, and fibroblasts have been considered to be the 
mediators of fibrosis, but new evidence points to a role 
for interstitial mast cells.33 We did not observe a signifi-
cant difference in collagen production, but colon length 
was significantly shorter in the chronic-colitis model. 
Graham et al. reported that the thickness of the muscu-
laris propria is also increased in colitis,34 which might 
also result in shortening of the intestine wall. Indirubin 
might have an effect on controlling the thickness of the 
muscularis propria in the chronic-colitis model. 
 Pro-inflammatory cytokines have been demonstrat-
ed to have a crucial role in IBD pathogenesis. Among 
these cytokines, higher expression of IL-6 has been 
demonstrated repeatedly.35 Naito et al. reported that 
DSS-induced inflammation appears to be inhibited 
significantly in IL-6−/− mice compared with wild-type 
mice. They suggested that persistent and marked block-
ade of IL-6 bioactivity provides some beneficial effects 
against intestinal inflammation.36 A clinical trial carried 
out recently in Japan clearly demonstrated the beneficial 
effects of humanized anti-IL-6 monoclonal antibody for 
treatment-resistant active Crohn’s disease.37 In our study, 
indirubin obviously suppressed the tissue level of IL-6 
in acute and chronic models of colitis, with a significant 
effect being observed in the chronic-colitis model. This 
finding could imply the crucial role of IL-6 in suppress-
ing DSS-induced colitis. Further studies are needed to 
clarify the precise relationship between indirubin and 
IL-6. Recently, Kawai et al. showed that Indigo naturalis 
and its major component indigo ameliorated murine 
DSS-induced colitis via upregulation of expression of 
IL-10 and IL-22 through activation of the aryl hydro-
carbon receptor.38 Further studies are needed to clarify 
the mechanisms of action of indirubin in preventing UC 
pathogenesis.
 We clearly proved that oral intake of indirubin can 
improve murine DSS-induced colitis (which mimics hu-
man IBD).39 Furthermore, we showed, for the first time, 
that indirubin is more effective in the acute phase than 
in the chronic phase. 
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